

Business and Scientific Update

Disclaimer

When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI's public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.

All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.

2015 Strategic Goals

- 1 Obtain Investigational New Drug (IND) Status for COTI-2 from the US FDA
- 2 Increase value of COTI-2 by identifying new clinical trial indications and combination therapies
- 3 Appoint Scientific Advisory Board for the clinical development of COTI-2 & other pipeline assets
- 4 Commence Phase 1 clinical trial for COTI-2 in patients with advanced gynecologic cancers
- 5 Select our next clinical candidate for development

#1: IND Status for COTI-2

April 2015

Filed our IND application

May 2015

IND status granted by U.S. Food and Drug Administration for COTI-2 in gynecologic cancers



#2: Identify New Indications/Comb. Therapies

- Exploring clinical trials for other indications:
 - Head and neck (orphan) 2016
 - Li-Fraumeni syndrome (orphan) 2016
 - AML (orphan)
 - NSCLC

- COTI-2 effective when combined with many first line therapies:
 - Chemotherapy
 - Immunotherapy – actively developing research collaborations



#3: Establish Scientific Advisory Board

March 2015

Established high-profile Scientific Advisory Board for the clinical development of COTI-2 and other pipeline assets

Chaired by Dr. Gordon Mills



#4: Commence Phase 1 for COTI-2

- Expected to commence October 2015 at MDACC
- Up to 46 women with gynecological cancers
 - Enriched with ovarian cancer patients
 - No chemo/radiation for at least 28 days prior to starting
 - Follow for up to 6 months of treatment
- Expected to take 18 months to complete
 - Interim data at ~ 9 months into the study

#5: Select Next Candidate for Development

Options are:

1. COTI-219, a unique oncology drug candidate for CRC and other cancers with RAS mutations
2. COTI-AML-01, a multi-kinase inhibitor for Acute Myelogenous Leukemia (AML)
3. COTI-HIV-II, second generation dual HIV Integrase inhibitor
4. COTI-MRSA1, highly novel antibiotic program

All potential candidates discovered by
our CHEMSAS[®] platform

CHEMSAS: Our Pipeline

Compound	Target	CHEMSAS®	Lead Selection	Synthesis	Preclinical	Phase 1
COTI-2 (p53)						
AML						
Colon						
COTI-219						
COTI-4						
COTI-58						
Other Programs*						

***Programs for MRSA, Multiple sclerosis, Alzheimer's, and HIV Integrase**


COTI-2

**A potential breakthrough
therapy for many cancers**


P53-dependent mechanism of action

- Demonstrated selective and potent anti-cancer activity in pre-clinical experiments
- Effective against many common cancers with a p53 gene mutation
- > 50% of all human cancers have a p53 mutation
(*e.g. ~ 95% of serous ovarian cancers*)

“a promising advance” for many cancers with p53 mutations.” – Dr. G.B. Mills, MDACC



COTI-2: Impressive single agent activity



Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control

- Granted by the FDA for the treatment of ovarian cancer – June 2014
- Potentially qualifies us for:
 - Assistance in clinical trial design
 - Expedited drug development – Fast track designation
 - Development grants & fee reductions
 - 7-year exclusive marketing period


- Orally bio-available and effective at low dose
- Low toxicity in preclinical development
- Opportunity for both single agent and combination therapy
- Strong US and international IP protection in place

Positive Phase 1 results will create important options:

- Out-license
 - Validates scientific platform and commercial strategy
 - May not realize maximum shareholder/asset value
- Phase 2
 - Moon shot project at MDACC possible
 - Maximizes asset value

Shareholder value creation 2015



COTI share price performance compared with TSX.V



Strategic goals for 2016

- 1 Guide COTI-2 to successful completion of first Phase 1 human trial and licensing deal
- 2 Identify and commence at least one additional Phase 1 clinical trial in 2016
- 3 Identify our next clinical candidate and drive it towards the clinic
- 4 Plan for strategic growth in the US
 - Boston based office
 - Uplift to NASDAQ listing

Thank you



2015 Annual General and Special Meeting of Shareholders